| INTRODUC TI ON
In patients with severe haemophilia A, prophylaxis using replacement factor VIII (FVIII) products has several established benefits with regard to prevention of joint bleeds and joint damage. [1] [2] [3] However, prophylaxis regimens typically require frequent infusions that can be cumbersome and lead to suboptimal treatment adherence. 4, 5 Longer-acting FVIII products with improved pharmacokinetic (PK) profiles have the potential to maintain FVIII levels above threshold levels for longer periods of time with higher FVIII levels between infusions, which may result in better protection from bleeding. 6, 7 PK parameters, such as incremental recovery, half-life (t ½ ), area under the curve (AUC) and clearance (CL), are considered to be the most important surrogate efficacy endpoints for new FVIII products, per the European Medicines Agency. 8 BAY 94-9027 is a B-domain-deleted recombinant FVIII (BDDrFVIII) product with a single (dual-branched) 60-kDa polyethylene glycol (PEG) molecule site-specifically attached via a maleimide linker to a cysteine amino acid. [9] [10] [11] Preclinical studies demonstrated full coagulation activity, comparable efficacy, similar binding to von
Willebrand factor and improved PK parameters for BAY 94-9027 compared with unmodified BDD-rFVIII or full-length rFVIII. 11, 12 In a phase 1 study in previously treated adults with severe haemophilia A, BAY 94-9027 demonstrated a longer t ½ and higher AUC compared with sucrose-formulated rFVIII (rFVIII-FS [Kogenate ® FS, Bayer, Berkeley, CA, USA]). 13 The PK characteristics of BAY 94-9027 were also assessed in a subset of patients from the phase 2/3 study in adults and adolescents (PROTECT VIII) 14 and in a phase 3 study in children (PROTECT VIII Kids). 15 Here, we report the PK properties of BAY 94-9027 in adults, adolescents and children with severe haemophilia A from the phase 1 (18-65 years), PROTECT VIII (12-65 years) and PROTECT VIII Kids (0-<12 years) trials combined.
| MATERIAL S AND ME THODS

| Study design
The phase 1 study (ClinicalTrials.gov identifier, NCT01184820) 
| Patients
| Pharmacokinetic assessments
Chromogenic assay (BIOPHEN FVIII:C, Aniara Diagnostica, West
Chester, OH, USA) was used for measurement of samples in all 3 studies; the one-stage assay was also used in the phase 1 and PROTECT VIII studies. Results reported in this manuscript are based on the chromogenic assay; similar results were obtained using the one-stage assay (data not shown). The PK parameters were calculated using the model-independent method and WinNonlin 
| VWF:Ag levels
Endogenous von Willebrand factor antigen (VWF:Ag) levels can influence the PK parameters of rFVIII. 16, 17 Therefore, baseline VWF:Ag levels were measured in the phase 1 study and PROTECT VIII. and rFVIII-FS PK parameters in the phase 1 study, point estimates (least-squares means) and 90% CIs were calculated based on an analysis of variance (ANOVA) on the log-transformed PK parameters by retransformation of the logarithmic results.
| Statistical analysis
| RE SULTS
| Baseline demographics
A total of 14 adults from the phase 1 study (7 patients age for the overall population was 6 (2-11) years; for patients aged <6 years and 6 to <12 years, median (range) ages were 3 (2-5) and 9 (6-11) years, respectively.
| Pharmacokinetics of BAY 94-9027 compared with sucrose-formulated recombinant factor VIII
In the phase 1 study, improved PK parameters were reported for BAY 94-9027 vs rFVIII-FS ( 
| Pharmacokinetic comparisons by age
PK characteristics of BAY 94-9027 were age dependent, which is consistent with other FVIII products. adults and higher in children; this is reflected in the plasma concentration curves shown in Figure 1 . The PK analysis based on age groups in the PROTECT VIII and PROTECT VIII Kids studies is shown in AUC and C max were lower, whereas V ss and CL were higher in children compared with adults and adolescents (Table 5) ; mean CL and V ss in the adolescent/adult population were 0.016 dL/h/kg and ~0.40 dL/kg, respectively, using combined data from the phase 1
and PROTECT VIII studies.
Lower observed values of AUC norm , C max,norm and t ½ in children compared with adults and adolescents after a 60-IU/kg infusion in all 3 studies are illustrated in Figure 2 . Between adults and adolescents, the range for the PK parameters overlapped and there were no relevant differences between these age groups.
| Correlation of VWF:Ag level with pharmacokinetic parameters
Correlations between VWF:Ag levels and log-transformed BAY 94-9027 t ½ and CL based on data from 34 adult patients in the AUC, area under the curve; AUC norm , dose-normalized area under the curve; CL, clearance; C max , maximum concentration; C max, norm , dose-normalized maximum concentration; CV, coefficient of variation; MRT IV , mean residence time after intravenous injection; t ½ , half-life; V SS , volume of distribution at steady state. FVIII levels were measured using the chromogenic assay. a n = 15.
phase 1 (n = 13) and PROTECT VIII (n = 21) studies are shown in 
| D ISCUSS I ON
BAY 94-9027 is an extended-half-life rFVIII product for treatment of patients with haemophilia A that was developed with the goal of providing good protection from bleeding with less frequent infusions. The longer t ½ compared with rFVIII-FS, an unmodified rFVIII product, and the efficacy when infused as infrequently as every 7 days has been previously reported. [13] [14] [15] Even more than t ½ , AUC for a FVIII product is an important PK parameter that can serve as a predictor of protection from bleeding. 21 The PK analysis for BAY 94-9027 showed higher AUC values in comparison with rFVIII-FS in the phase 1 study 13 ; these higher AUC values were confirmed in the phase 2/3 study.
The improved PK properties are further explored in this analysis, which includes data from 3 separate studies, and across 4 different patient age groups. The data confirm the early observations of the improved PK profile and provide evidence that treatment with BAY 94-9027 could result in improved clinical outcomes due to higher circulating levels over time, as measured by both longer t ½ and higher AUC. Additionally, these PK improvements are observed in adults, adolescents and children. The PK parameters were similar after single- to what has been reported previously in patients treated with other rFVIII products. 16, [22] [23] [24] This suggests that the interaction with VWF:Ag is the same as would be expected for an unmodified FVIII product.
PK characteristics of BAY 94-9027 were age dependent, which is consistent with other FVIII products. [18] [19] [20] 25, 26 This may be explained by the nonlinear relationship between CL and body weight (or lean body weight); this is described by allometric scaling and has been reported previously for other FVIII concentrates. 27, 28 Body weight-based dosing assumes a linear increase in CL in relation to body weight leading to overcorrection of CL and lower exposure in children than adults.
Ideally, PK properties of different products should be compared when they are investigated in the same population using a crossover study design and appropriate assay methods for sample analysis.
However, indirect comparisons can also provide useful information on the possible trend in PK parameters across products. Based on available published data, BAY 94-9027 appears to have a comparable or improved PK profile, including t ½ and AUC, in all patient age groups vs other extended-half-life rFVIII products by indirect comparison. 19, 20, 29, 30 During prophylactic replacement therapy, increased time per week spent with low FVIII levels (<1%) is known to be a determinant of breakthrough bleeding risk, especially in children. 31 Similarly, time spent with FVIII levels >20%, high FVIII peak levels and AUC have been associated with reduced bleeding. 21 These data suggest that improved PK profiles, including longer t ½ and higher AUC, may provide additional bleeding protection. 7, 21, 32 Low bleeding rates were observed with BAY 94-9027 prophylaxis in the PROTECT VIII and PROTECT VIII Kids studies 14, 15 ; however, only direct comparisons can truly assess the effects of improved PK profiles on bleeding.
F I G U R E 2 PK parameters analysed by age group after a 60-IU/kg infusion in the phase 1 (cohort 2 only), PROTECT VIII and PROTECT VIII Kids trials in children, adolescents and adults. A, t ½ , B, AUC norm and C, C max,norm were determined based on the chromogenic assay. The horizontal bars in each panel show the geometric mean values for the PK parameters in each age group. AUC norm , dose-normalized area under the curve; C max,norm , dosenormalized maximum concentration; PK, pharmacokinetic; t ½ , half-life
| CON CLUS IONS
In summary, BAY 94-9027 demonstrated a longer t ½ and higher AUC compared with rFVIII-FS (as previously reported). No relevant changes in PK characteristics were observed after multiple doses.
The PK characteristics were comparable between adolescents and adults. The longer t ½ and higher AUC for BAY 94-9027 compared with rFVIII-FS (and other rFVIII products by indirect comparison)
suggests that patients can be above threshold levels for longer duration, with higher FVIII levels between infusions and therefore can extend the interval between prophylaxis infusions while maintaining low bleeding rates.
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